|
Found 8 result(s) FROM 1963 pages containing the term 'myeloid leukemia'.
Wednesday Aug 05, 2009
Lupus with Leucopenia, Anemia Signals Risk of Leukemia
Lupus patients with persistent leucopenia or anemia may be at risk for myeloid leukemia...
Wednesday Jul 09, 2008
Lasting Leukemia Risk for AS Patients Treated With Now Banned 224Radium (SpondylAT®)
AS patients who were treated with repeated intravenous injections of 224Radium (SpondylAT®) are at increased risk for developing leukemia…
Wednesday Nov 29, 2006
KaloBios Initiates Phase I Clinical Trial of Anti-GM-CSF Antibody for Rheumatoid Arthritis
KaloBios Pharmaceuticals, Inc, a privately-held clinical development company focused on the development of therapeutic antibodies, announced that it has begun treating patients in a phase I clinical trial of its investigational rheumatoid arthritis (RA) therapeutic, KB002, an engineered chimeric human monoclonal antibody targeting the cytokine growth factor, granulocyte macrophage colony-stimulating factor (GM-CSF).
Wednesday Jul 19, 2006
TeGenero Files for Insolvency as Investors Evaporate Following Disastrous First-In-Man Phase I Trial of Superagonistic Anti-CD28 Antibody for Autoimmune Diseases and Leukemia
TeGenero AG has filed for the commencement of insolvency proceedings at the competent local court/insolvency court because the serious adverse reactions caused by the investigational agent TGN1412 in the March 2006, first-in-man, phase I trial made it impossible to attract the investment necessary for the company to continue operations.
Monday Jul 17, 2006
LTKfarma Starts Operations With Lead Product for Autoimmune Diseases and Leukemia Already in Phase I/II, Names Advisory Board
LTKfarma, a biopharmaceutical company founded in March 2006 and focused on developing and marketing cell therapy products derived from modified T-cells to treat autoimmune diseases and leukemia announced its creation and the appointment of its advisory board....
Monday Mar 20, 2006
Trial Halted of TeGenero's Study Drug TGN1412 (CD28-SuperMAB®) for Autoimmune Diseases and Leukemia; Six Hospitalized Following Serious Adverse Reactions
TeGenero AG, of Würzburg, Germany, announced that six subjects participating in a clinical trial evaluating the safety of its study drug TGN1412...
Tuesday Nov 29, 2005
Mycophenolate Mofetil (MMF) More Effective Than Cyclophosphamide in Lupus Nephritis
Mycophenolate mofetil (MMF), an immunosuppressive agent approved for the prevention of transplant rejection, may emerge as an effective alternative to IV cyclophosphamide, the current standard of care for lupus nephritis patients... Ginzler, EM, et al. N Engl J Med. 2005;353:2219-2228.
Monday Oct 18, 2004
Genomics Research Pioneer Foresees Breakthroughs, Challenges in Gene-Targeted Therapy
The Director of the Human Genome Research Institute urges rheumatology researchers to take advantage of new technology to identify genes involved in inflammatory autoimmune diseases…
|
